lenalidomide

March 28, 2019

Revlimid/Rituxan Combo Shows Promise in Follicular, Marginal Zone Lymphomas

News

Patients with follicular lymphoma and marginal zone lymphoma who failed at least one prior therapy live significantly longer — more than two years — without their disease worsening when treated with a combination ... Read more

September 19, 2018September 19, 2018

Rituxan-Revlimid Combo Effective in Treating Advanced Follicular Lymphoma, Study Shows

News

Patients with previously untreated follicular lymphoma may soon be able to replace a regimen of chemotherapy and Rituxan (rituximab) with Rituxan and Revlimid (lenalidomide) after a Phase 3 trial showed similar effectiveness for ... Read more

July 30, 2018July 31, 2018

Revlimid-Rituxan Combo May Replace Chemo, Delay Decline for Some Lymphoma Patients, Phase 3 Trial Shows

News

Adding Revlimid (lenalidomide) to Rituxan (rituximab) in the treatment of follicular lymphoma and marginal zone lymphoma patients who failed at least one prior therapy significantly delays disease progression or death, a Phase 3 ... Read more

March 19, 2018March 19, 2018

MorphosSys Therapy and Revlimid Eliminate Cancer in a Third of DLBCL Patients, Phase 2 Trial Shows

News

A combination of MorphoSys‘ MOR208 and Revlimid (lenalidomide) eliminated cancer cells in almost a third of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a Phase 2 clinical trial shows. Tumor ... Read more

February 9, 2018February 9, 2018

Triple Combo Therapy Improves Outcomes for Certain Mantle Cell Lymphoma Patients

News

Combining Imbruvica (ibrutinib) with Revlimid (lenalidomide) and Rituxan (rituximab) may improve the poor outcomes of relapsed mantle cell lymphoma patients with certain genetic alterations, a Phase 2 trial suggests. But ... Read more

December 8, 2017December 8, 2017

Phase 2 Trial Testing Gazyva Combo Regimens in Relapsed Follicular Lymphoma Now Enrolling Participants

News

Biopharmaceutical company TG Therapeutics and the National Cancer Institute’s SWOG have initiated a Phase 2 trial testing three Gazyva (obinutuzumab) regimens in patients with relapsed or refractory follicular lymphoma. The ... Read more

November 3, 2017

MorphoSys’ MOR208 Receives Breakthrough Therapy Status in US for Relapsed or Refractory DLBCL

News

The U.S. Food and Drug Administration has granted breakthrough therapy designation to MorphoSys‘ MOR208 – in combination with Revlimid (lenalidomide) – for the treatment of adult patients with relapsed or refractory diffuse ... Read more

July 18, 2017July 18, 2017

Revlimid-Rituxan Combo Proves Effective Against Hard-to-Treat Non-Hodgkin’s Lymphomas, Trial Shows

News

Seventy percent of follicular lymphoma patients treated with a combination of Revlimid and Rituxan went a year without their cancer progressing, according to interim Phase 3 clinical trial results. Celgene, which developed Relimid, ... Read more

August 1, 2016August 1, 2016

Revlimid Fails to Improve Overall Survival of Diffuse Large B-Cell Lymphoma For Certain Patients

News

Patients with diffuse large B-cell lymphoma (DLBCL) who respond to first line Rituxan/Mabthera (rituximab) plus CHOP chemotherapy (R-CHOP) induction therapy may have increased progression-free survival when treated with Revlimid (lenalidomide) ... Read more

July 27, 2016July 27, 2016

Revlimid Approved to Treat Relapsed/Refractory Mantle Cell Lymphoma in EU

News

The European Commission has approved Revlimid (lenalidomide), produced by Celgene, for adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, including bortezomib. Refractory mantle cell ... Read more